相关实验视频
Updated: Jan 10, 2026

11:10
Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
Published on: November 16, 2011
95.6K
在GLP-1RA疗法下的葡萄糖抑制:肌肉和弹性隐藏的权衡
Torsak Tippairote1,2,3, Pruettithada Hoonkaew2,3,4, Aunchisa Suksawang2,3
1School of Health Sciences, Sukhothai Thammathirat Open University, Pak Kret District, Nonthaburi, 11120 Thailand.
Diabetology international
|November 28, 2025
概括
类似葡萄糖-1受体激动剂 (GLP-1RAs) 可能通过抑制葡萄糖导致肌肉损失,从而损害营养使用. 对长期使用者来说,监测肌肉健康和氨基酸代谢是至关重要的.
科学领域:
- 内分泌学和新陈代谢学
- 药理学 药理学是指药理学的学科.
- 肌肉生理学 肌肉生理学
背景情况:
- 类似葡萄糖-1受体激动剂 (GLP-1RAs) 是有效的2型糖尿病和肥胖管理.
- GLP-1RA疗法始终与瘦肉质量损失有关,这种副作用不能完全由减少摄入量或肌肉重塑来解释.
- 持续的葡萄糖抑制被认为是推动这种肌肉衰减的关键,但却被忽视的机制.
研究的目的:
- 为了研究持续抑制GLP-1RA相关的瘦肉质量损失中的葡萄糖的作用.
- 了解慢性葡萄糖抑制如何影响肝脏氨基酸清除和肌肉蛋白解.
- 突出催产素营养不良的潜力及其对肌肉健康和性的长期影响.
主要方法:
- 对GLP-1RA影响现有的临床试验数据的审查.
- 对涉及葡萄糖抑制的拟议系统机制的分析.
- 代谢途径分析将葡萄糖与氨基酸代谢和肌肉蛋白平衡联系起来.
主要成果:
- 通过GLP-1RAs持续抑制葡萄糖素可能会损害肝脏氨基酸清除.
- 这种损伤会改变基质的供应,可能促进肌肉蛋白质分解.
- 慢性葡萄糖沉默可以侵蚀适应能力,增加特定人群的脆弱性.
结论:
- 持续的葡萄糖抑制是GLP-1RA诱导的瘦质量损失的一个合理的机制.
- 这种效应可以被概念化为药物诱导的营养不匹配或阳性营养不良.
- 建议长期使用GLP-1RA的人定期监测肌肉功能和氨基酸代谢,以减轻风险并保持弹性.
相关概念视频
Glucagon-like Receptor Agonists
820
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
820
Hypoglycemia and Glucagon
778
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
778
Hormones Regulating Blood Glucose
6.3K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
6.3K
Insulin: Dosing Regimen and Adverse Effects
658
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
658
Oral Hypoglycemic Agents: Glinides
572
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
572
Glucose Homeostasis: Regulation of Blood Glucose
3.7K
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
3.7K

